Kiora Pharmaceuticals Q1 Financial Analysis
Written by Emily J. Thompson, Senior Investment Analyst
Updated: 2 days ago
0mins
Should l Buy KPRX?
Source: seekingalpha
- Earnings Performance: Kiora Pharmaceuticals reported a Q1 GAAP EPS of -$0.58, indicating challenges in profitability that may affect investor confidence and stock price performance.
- R&D Expense Changes: Research and development expenses were approximately $2.1 million, a decrease from $2.5 million in the prior year, primarily reflecting adjustments in clinical activity timing and collaboration credits, indicating a strategic shift in resource allocation.
- Slight Increase in Admin Costs: General and administrative expenses were around $1.6 million, up from $1.5 million in Q1 2025, suggesting that the company needs to enhance cost control in its operational management.
- Impact of Collaboration Revenue: Kiora recognized $1.2 million in reimbursable expenses from Théa within its R&D costs, down from $2.0 million in the previous year, highlighting the potential financial impact of fluctuations in collaborative relationships.
Trade with 70% Backtested Accuracy
Stop guessing "Should I Buy KPRX?" and start using high-conviction signals backed by rigorous historical data.
Sign up today to access powerful investing tools and make smarter, data-driven decisions.
Analyst Views on KPRX
Wall Street analysts forecast KPRX stock price to rise
1 Analyst Rating
1 Buy
0 Hold
0 Sell
Moderate Buy
Current: 2.450
Low
12.00
Averages
12.00
High
12.00
Current: 2.450
Low
12.00
Averages
12.00
High
12.00
About KPRX
Kiora Pharmaceuticals, Inc. is a clinical-stage pharmaceutical company, which is engaged in developing and commercializing therapies for the treatment of retinal diseases. The Company is engaged in developing KIO-301, a vision-restoring small molecule that acts as a photoswitch specifically created to restore vision in patients with inherited and age-related degenerative retinal diseases, including retinitis pigmentosa (RP). It is also developing KIO-104 for the treatment of retinal inflammatory diseases, including Diabetic Macular Edema (DME) and Posterior Non-Infectious Uveitis, a rare T cell-mediated, intraocular inflammatory disease. KIO-104 is a non-steroidal small-molecule inhibitor of dihydroorotate dehydrogenase (DHODH) formulated for intravitreal delivery and is ideally suited to suppressing overactive T-cell activity to treat the underlying inflammation. KIO-101 focuses on treating the ocular manifestation of patients with autoimmune diseases.
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
Kiora Pharmaceuticals Q1 Financial Analysis
- Earnings Performance: Kiora Pharmaceuticals reported a Q1 GAAP EPS of -$0.58, indicating challenges in profitability that may affect investor confidence and stock price performance.
- R&D Expense Changes: Research and development expenses were approximately $2.1 million, a decrease from $2.5 million in the prior year, primarily reflecting adjustments in clinical activity timing and collaboration credits, indicating a strategic shift in resource allocation.
- Slight Increase in Admin Costs: General and administrative expenses were around $1.6 million, up from $1.5 million in Q1 2025, suggesting that the company needs to enhance cost control in its operational management.
- Impact of Collaboration Revenue: Kiora recognized $1.2 million in reimbursable expenses from Théa within its R&D costs, down from $2.0 million in the previous year, highlighting the potential financial impact of fluctuations in collaborative relationships.
See More
KIORA PHARMACEUTICALS INC Reports Q1 Loss of $0.58 Per Share in SEC Filing
Financial Performance: Kiora Pharmaceuticals reported a loss of $0.58 per share for the first quarter.
Regulatory Filing: The company has submitted a filing with the Securities and Exchange Commission (SEC) regarding its financial results.
See More
Kiora Pharmaceuticals Secures $24 Million Financing to Advance Eye Disease Treatments
- Financing Structure: Kiora Pharmaceuticals has secured $24 million through a private placement, which includes $5 million in upfront proceeds and $19 million linked to warrant exercises, indicating strong investor confidence in its eye disease treatment pipeline.
- Stock Price Reaction: KPRX shares surged over 17% in pre-market trading on Tuesday, and if these levels hold after the opening bell, the stock would reach its highest point in over two months, reflecting a positive market response to the new financing.
- R&D Progress: Kiora has recently advanced its treatment for retinitis pigmentosa, with KIO-301 entering the patient dosing phase in the Phase 2 ABACUS-2 trial, further enhancing the potential of its research pipeline.
- Market Sentiment: Retail sentiment on Stocktwits shifted from 'bullish' to 'extremely bullish', although some users expressed concerns about the stock potentially falling below $1 by the end of the week, indicating mixed views on KPRX's future performance.
See More
KIORA PHARMACEUTICALS INC TO OFFER 438,471 COMMON STOCK SHARES THROUGH PRIVATE PLACEMENT - SEC FILING
Company Overview: Kiora Pharmaceuticals is involved in the development and commercialization of pharmaceutical products, focusing on innovative therapies.
Stock Information: The company has issued 438,471 shares of common stock in a private placement, indicating a move to raise capital for its operations.
See More
Kiora Pharmaceuticals Reports FY 2025 Financial Results
- Financial Performance: Kiora Pharmaceuticals reported a GAAP EPS of -$2.64 for FY 2025, indicating challenges in profitability that may affect investor confidence.
- Cash Position: As of 2025, the company holds $17.1 million in cash, cash equivalents, and short-term investments, alongside $3.5 million in receivables, raising concerns about the sustainability of operational funding despite available resources.
- Operating Expenses: The net cash used in operating activities was $2.2 million for Q4 and $10.0 million for the full year, reflecting significant cash burn in operations that could impact future investment decisions.
- Funding Outlook: Based on current operational plans, Kiora expects its existing cash and short-term investments to fund operations into late 2027, beyond anticipated topline data readouts for ABACUS-2 and KLARITY, demonstrating a degree of financial foresight.
See More
Kiora Pharmaceuticals Joins RARE-X Vision Consortium Promoting Collaboration and Development of New Treatments for Rare Ocular Disorders
Kiora Pharmaceuticals Joins RARE-X Vision Consortium: Kiora Pharmaceuticals has partnered with Global Genes to join the RARE-X Vision Consortium, aimed at enhancing collaboration among stakeholders to develop therapies for rare ocular disorders.
Goals of the Vision Consortium: The consortium focuses on patient identification, recruitment, and developing meaningful outcome measures for clinical trials, while integrating patient voices into study designs to improve the lives of those affected by rare vision disorders.
See More
Kiora Pharmaceuticals Q1 Financial Analysis
- Earnings Performance: Kiora Pharmaceuticals reported a Q1 GAAP EPS of -$0.58, indicating challenges in profitability that may affect investor confidence and stock price performance.
- R&D Expense Changes: Research and development expenses were approximately $2.1 million, a decrease from $2.5 million in the prior year, primarily reflecting adjustments in clinical activity timing and collaboration credits, indicating a strategic shift in resource allocation.
- Slight Increase in Admin Costs: General and administrative expenses were around $1.6 million, up from $1.5 million in Q1 2025, suggesting that the company needs to enhance cost control in its operational management.
- Impact of Collaboration Revenue: Kiora recognized $1.2 million in reimbursable expenses from Théa within its R&D costs, down from $2.0 million in the previous year, highlighting the potential financial impact of fluctuations in collaborative relationships.
See More
KIORA PHARMACEUTICALS INC Reports Q1 Loss of $0.58 Per Share in SEC Filing
Financial Performance: Kiora Pharmaceuticals reported a loss of $0.58 per share for the first quarter.
Regulatory Filing: The company has submitted a filing with the Securities and Exchange Commission (SEC) regarding its financial results.
See More
Kiora Pharmaceuticals Secures $24 Million Financing to Advance Eye Disease Treatments
- Financing Structure: Kiora Pharmaceuticals has secured $24 million through a private placement, which includes $5 million in upfront proceeds and $19 million linked to warrant exercises, indicating strong investor confidence in its eye disease treatment pipeline.
- Stock Price Reaction: KPRX shares surged over 17% in pre-market trading on Tuesday, and if these levels hold after the opening bell, the stock would reach its highest point in over two months, reflecting a positive market response to the new financing.
- R&D Progress: Kiora has recently advanced its treatment for retinitis pigmentosa, with KIO-301 entering the patient dosing phase in the Phase 2 ABACUS-2 trial, further enhancing the potential of its research pipeline.
- Market Sentiment: Retail sentiment on Stocktwits shifted from 'bullish' to 'extremely bullish', although some users expressed concerns about the stock potentially falling below $1 by the end of the week, indicating mixed views on KPRX's future performance.
See More
KIORA PHARMACEUTICALS INC TO OFFER 438,471 COMMON STOCK SHARES THROUGH PRIVATE PLACEMENT - SEC FILING
Company Overview: Kiora Pharmaceuticals is involved in the development and commercialization of pharmaceutical products, focusing on innovative therapies.
Stock Information: The company has issued 438,471 shares of common stock in a private placement, indicating a move to raise capital for its operations.
See More
Kiora Pharmaceuticals Reports FY 2025 Financial Results
- Financial Performance: Kiora Pharmaceuticals reported a GAAP EPS of -$2.64 for FY 2025, indicating challenges in profitability that may affect investor confidence.
- Cash Position: As of 2025, the company holds $17.1 million in cash, cash equivalents, and short-term investments, alongside $3.5 million in receivables, raising concerns about the sustainability of operational funding despite available resources.
- Operating Expenses: The net cash used in operating activities was $2.2 million for Q4 and $10.0 million for the full year, reflecting significant cash burn in operations that could impact future investment decisions.
- Funding Outlook: Based on current operational plans, Kiora expects its existing cash and short-term investments to fund operations into late 2027, beyond anticipated topline data readouts for ABACUS-2 and KLARITY, demonstrating a degree of financial foresight.
See More
Kiora Pharmaceuticals Joins RARE-X Vision Consortium Promoting Collaboration and Development of New Treatments for Rare Ocular Disorders
Kiora Pharmaceuticals Joins RARE-X Vision Consortium: Kiora Pharmaceuticals has partnered with Global Genes to join the RARE-X Vision Consortium, aimed at enhancing collaboration among stakeholders to develop therapies for rare ocular disorders.
Goals of the Vision Consortium: The consortium focuses on patient identification, recruitment, and developing meaningful outcome measures for clinical trials, while integrating patient voices into study designs to improve the lives of those affected by rare vision disorders.
See More
